Custom Health IFRS net loss widens to US$33.4 million in FY26 Q2; revenue climbs 70% to US$7.4 million

• Custom Health posted Q2 revenue of US$7.4 million, up 70% year over year; IFRS net loss widened to US$33.4 million.
• Loss was driven mainly by a one-time, largely non-cash US$22.4 million IFRS 2 listing expense tied to the reverse takeover.
• Gross profit rose 43% to US$2.9 million; gross margin fell 7.4 percentage points to 39.3%.
• Non-IFRS adjusted EBITDA loss widened to US$3.3 million; adjusted EBITDA margin improved to -44.4% from -70%.
• Signed deals for Evergreen Pharmacy, expected to add over US$78 million annual revenue, and Spencer Health; targets over US$130 million run-rate by end-2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Custom Health Holdings Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202608171807NEWSFILECNPR____20260817_310104_1) on August 17, 2026, and is solely responsible for the information contained therein.